TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05577377

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Orgasmic Meditation
Description: Orgasmic Meditation (OM) is a structured attention training practice that you do with another person by following a predefined set of detailed instructions. One of the two people participating in the OM must have a clitoris. In this partnered practice, one person strokes the clitoris of another person with the tip of their left index finger for 15 minutes.
Study: NCT04808947

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia
Description: Procedure: Local infiltration analgesia performed by surgeons.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local infiltration analgesia
Description: Procedure: Local infiltration analgesia performed by surgeons.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided adductor canal block
Description: Procedure: Ultrasound-guided adductor canal and iPACK blocks performed by anesthesiologists preoperatively.
Study: NCT04667520

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Physical Activity (LPA)
Description: This intervention has 3 components: (1) an orientation session to LPA and using the Fitbit; (2) Six telephone physical activity counseling sessions; and (3) monitoring activity with the Fitbit, which is provided to them during their study participation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit Only
Description: Participants are provided with a Fitbit during their study participation.
Study: NCT05302206

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: colonic infusion
Description: colonic glucose or colonic saline infusion

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: colonic infusion
Description: colonic glucose or colonic saline infusion
Study: NCT06582953

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Turning the Tide Violence Intervention Program (hospital violence intervention program)
Description: TTVIP is already integrated into the regular care of patients who are violently injured and treated at MUSC Charleston. Client advocates provide immediate support, help with communication and provide anti-retaliation messaging to victims of violence and their families, in addition to helping support their healthcare. Patients that opt to be followed for long-term wrap-around services and live in the surrounding 3-county area are supported for months (up to 1 year) after injury and provided mentorship, service referrals (i.e. education, employment, substance abuse, injury recovery, pro-social activities, housing) and mental health services.
Study: NCT05481645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450 injection
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents the binding of PD-L1 to PD-1 and B7.1 receptors on the surface of T cells, thereby reactivating T cells and enhancing the immune response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450 injection
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents the binding of PD-L1 to PD-1 and B7.1 receptors on the surface of T cells, thereby reactivating T cells and enhancing the immune response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450 injection
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents the binding of PD-L1 to PD-1 and B7.1 receptors on the surface of T cells, thereby reactivating T cells and enhancing the immune response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride Capsule
Description: Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride Capsule
Description: Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin Injection
Description: Carboplatin which s similar to alkylating agent, is a second-generation platinum anti-tumor drug, which mainly causes cross-linking of DNA within and between chains, destroys DNA molecules, and disintegrates the helix.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin Injection
Description: Carboplatin which s similar to alkylating agent, is a second-generation platinum anti-tumor drug, which mainly causes cross-linking of DNA within and between chains, destroys DNA molecules, and disintegrates the helix.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel Injection
Description: Paclitaxel is a diterpene alkaloid with anticancer activity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel Injection
Description: Paclitaxel is a diterpene alkaloid with anticancer activity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride Injection
Description: Doxorubicin hydrochloride is a cycle non-specific anticancer chemotherapy drug, which directly acts on DNA, changes the nature of DNA template, and inhibits DNA polymerase.
Study: NCT05907005

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iCBT-based EMI
Description: Consists of brief iCBT for psychological support (mandatory), stroke care education (optional), and nurse-led real-time chat-based support messages, delivered according to participants' preferences.
Study: NCT05916625

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuropsychological assessment
Description: a consultation to assess cognitive and psycho-behavioral functions with questionnaires

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: biological sample
Description: 10 mL intravenous whole blood collection in EDTA tube

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: medical imagery
Description: Pet scan with the specific radioligand \[11C\]SB207145 and MRI
Study: NCT05526144

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Synthroid
Description: Synthroid tablets 25 mcg. Subjects in the study group will receive Synthroid at a titrated dose of 25 mcg (one tablet), 50 mcg (two tablets), or maximum of 75 mcg (3 tablets) daily for one year duration that will maintain TSH at normal level.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets 25 mcg daily. Subjects in the placebo group will receive placebo tablets at a dose of 25 mcg (one tablet), 50 mcg (two tablets), or maximum of 75 mcg (3 tablets) daily for a one year duration.
Study: NCT05685563

Intervention type: DIAGNOSTIC_TEST
Intervention: DIERS formetic 4D
Description: Assessment of mentioned tests and their comparison.

Intervention type: DIAGNOSTIC_TEST
Intervention: DIERS formetic 4D
Description: Assessment of mentioned tests and their comparison.

Intervention type: DIAGNOSTIC_TEST
Intervention: DIERS formetic 4D
Description: Assessment of mentioned tests and their comparison.
Study: NCT06142396

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Daratumumab-hyaluronidase in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone
Description: This intervention is Daratumumab-hyaluronidase in combination with the chemotherapy regimen CyBord (cyclophosphamide, bortezomib, and dexamethasone) and then with lenalidomide maintenance in patients with newly diagnosed multiple myeloma who have new onset renal failure.
Study: NCT05006404

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulmonary Valve Replacement Surgery
Description: Pulmonary valve replacement surgery with the Autus Valve
Study: NCT06567886

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light Therapy
Description: Participants will self-administer the daily light therapy within a few minutes of their assigned wake up time for one hour.~Researchers will provide a light log to note light on/off times, any interruptions to light therapy, and primary activity during light therapy.
Study: NCT05481645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride Injection
Description: Gemcitabine is a cell cycle specific antimetabolic drug, which mainly acts on tumor cells at the DNA synthesis stage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel injection
Description: Docetaxel is an anti-tumor drug of paclitaxel, which plays an anti-tumor role by interfering with the microtubule network necessary for cell Mitosis and interphase cell function.
Study: NCT05723276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Psilocybin 25mg PO
Study: NCT06272279

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: spinal stimulation-DCS
Description: transcutaneous spinal stimulation by direct current stimulation

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: spinal stimulation-sham DCS
Description: sham transcutaneous spinal stimulation by direct current stimulation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: spinal stimulation-EPS
Description: transcutaneous spinal stimulation by electrical pulsed stimulation

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham spinal stimulation-EPS
Description: sham transcutaneous spinal stimulation by electrical pulsed stimulation
Study: NCT06567886

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Stabilization
Description: All participants will be asked to follow a fixed sleep schedule.
Study: NCT05288179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone Capsules
Description: After randomization, the experimental group took pirfenidone capsules 3 times a day，Week 1, 2 capsules/time; Week 2, 4 capsules/time; Week 3-52, 6 capsules/time

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo capsules
Description: After randomization, the experimental group took placebo capsules 3 times a day，Week 1, 2 capsules/time; Week 2, 4 capsules/time; Week 3-52, 6 capsules/time
Study: NCT06409975

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Self-Compassion (MSC)
Description: MSC is an 8-week virtual intervention with weekly 2.5-hour sessions and a 4-hour retreat (between sessions 5 and 6) which will take place online via HIPAA-compliant Zoom. Each weekly session includes an opening meditation, reflection on weekly practice, short teaching, a weekly core meditation or informal practice discussion, short break, brief centering practice, weekly core reflective activity and discussion, and self compassion skill of the week practice. The 4-hour retreat is focused on engaging with the formal practices that have been taught in weeks 1-5.
Study: NCT05745506

Intervention type: OTHER
Description: Not applicable, there is no intervention description in this study.

Intervention type: OTHER
Description: Not applicable, there is no intervention description in this study.
Study: NCT05734703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nutraceutical Topical
Description: Once daily application of the topical nutraceutical to two by two inch area of skin for 90 days.
Study: NCT02615808

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen saturation data visualization
Description: The data visualization contains current and recent (over last 4, 8 or 12 hours) pulse oximetry readings and trends as well as the monitor alarm limits and most recently recorded supplemental oxygen content and flow.
Study: NCT05746572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA
Description: Participants will receive MDMA HCl (100 mg, 84 mg MDMA) in combination with massed exposure therapy for PTSD.
Study: NCT05421585

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: observational drug study
Description: Postoperative opioid consumption will be evaluated by applying 2 different block methods to patients who have undergone lumbar disc surgery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: observational drug study
Description: Postoperative opioid consumption will be evaluated by applying 2 different block methods to patients who have undergone lumbar disc surgery
Study: NCT06339281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apatinib mesylate+Capecitabine Tablets
Description: Apatinib Mesylate Tablets: 500 mg, qd, orally until disease progression or intolerable adverse reactions.~Capecitabine Tablets: 1000 mg/m2, po, twice a day, d1-d14, discontinued for 1 week after 2 weeks of treatment;

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: apatinib mesylate+Fulvestrant injection
Description: Apatinib Mesylate Tablets: 500 mg, qd, orally until disease progression or intolerable adverse reactions.~Fulvestrant injection 500 mg, intramuscular injection, q4w, once on d1 and d15 in the first cycle;
Study: NCT06065241

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LLP-01
Description: Participants in the experimental group will take 2 capsules daily containing 1,000mg of the formulation, LLP-01, for 60 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in the placebo group will take 2 capsules daily containing rice flower and small amount of Curcuma Longa for 60 days.
Study: NCT05790967

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sexual Education
Description: Women in the experimental group will be given education on sexual life during pregnancy. Before the training, preliminary data will be collected and then the participants will be given two hours of individual and face-to-face training.
Study: NCT05400811

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MM09 allergoid-mannan conjugates subcutaneous (3.000 UTm/mL)
Description: Mixture of allergen extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae conjugated to mannan at 3.000 UTm/mL for subcutaneous administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MM09 allergoid-mannan conjugates Sublingual (3.000 UTm/mL)
Description: Mixture of allergen extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae conjugated to mannan at 3.000 UTm/mL for sublingual administration.
Study: NCT05491369

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Epilepsy application
Description: Nanacara is an epilepsy application which helps people with epilepsy to self-manage their conditions.
Study: NCT06339502

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Jigsaw Technique
Description: The jigsaw technique is one of the cooperative learning methods. A topic planned to be learned in the lesson is divided into sections and these sections are distributed to the students in the main group. Students who are responsible for the same sections in the groups combine to form expert groups and specialize by working on the subject. They then return to their main group to share their knowledge and make a presentation on the topic.
Study: NCT06281119

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervavac as three dose regimen
Description: Cervavac manufactured by Serum Institute of India Pvt Ltd administered as three doses at day 0, 60 and 180.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervavac as two dose regimen
Description: Cervavac manufactured by Serum Institute of India Pvt Ltd administered as two doses at day 0 and 180.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Gardasil as three dose regimen
Description: Gardasil manufactured by MSD administered as a three doses at day 0,60 and 180.
Study: NCT06315439

Intervention type: PROCEDURE
Intervention: Endoscopic ultrasound fine needle biopsy
Description: EUS FNA/B for solid pancreatic lesions. After the FNA/FNB, the needle was removed from the EUS endoscope and the specimen obtained after the first needle pass was expelled and placed directly in a dedicated scaffold (Cytomatrix, UCS Diagnostics).~a drop of ethanol was put on it and the liquid was drained away thanks to the porous structure of the matrix. This step was followed by the deposition of a drop of acridine-orange for 20 and a rapid washing with buffered saline. After that, the Cytomatrix was put on a dedicated microscopic slide and covered with a second slide before the introduction in the slot of the machine.~The FCM VivaScope® 2500 (2500M-G4; VivaScope, Munich, Germany) was used for immediate imaging.
Study: NCT05488405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalamine Oral Product
Description: Mesalamine oral suspension for oral use
Study: NCT05226325

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: patients will receive after induction of anesthesia DEX at 1 mcg/kg for 10 minute followed by infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: patients will receive after induction of anesthesia DEX at 1 mcg/kg for 10 minute followed by infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: patients will receive after induction of anesthesia DEX at 1 mcg/kg for 10 minute followed by infusion
Study: NCT04192357

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WLM3P
Description: 18 months behavioral weight loss program divided into three phases (first and second phase of weight loss, during 1 month and 5 months, respectively; and a third phase of weight maintenance, during 12 months).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low-carb diet
Description: 18 months behavioral weight loss program divided in two phases (first of weight loss during 6 months and a second phase of weight maintenance during 12 months).
Study: NCT05153681

Intervention type: OTHER
Intervention: Peloid Therapy
Description: Peloid therapy; A total of 10 sessions were applied for 30 minutes by heating the proximal part of the sole of the foot, including the heel part, at a temperature of 45 degrees. Kinesioband application: One strip is prepared as a rake with a length of about 25 cm, and the other strip is prepared as an I tape with a length of about 20 cm. The ankle is in a neutral position of 90 degrees. Lymphatic and mechanical correction technique is applied. Afterwards, the band is activated.
Study: NCT05122026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifapentine
Description: As included in arm/group description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifapentine
Description: As included in arm/group description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: As included in arm/group description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: As included in arm/group description
Study: NCT05985265

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fat grafting
Description: Nano fat grafting followed by fractional carbon dioxide laser resurfacing
Study: NCT05400811

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MM09 allergoid-mannan conjugates Sublingual (9.000 UTm/mL)
Description: Mixture of allergen extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae conjugated to mannan at 9.000 UTm/mL for sublingual administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo subcutaneous
Description: The same solution, presentation, method of administration, frequency, and duration as the active treatment, but without active ingredients.
Study: NCT05175768

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinamide Mononucleotide
Description: Two sachets to be taken orally after breakfast and Two sachets after lunch with water.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinamide Mononucleotide with L-Leucine
Description: Two sachets to be taken orally after breakfast and Two sachets after lunch with water.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two sachets to be taken orally after breakfast and Two sachets after lunch with water.
Study: NCT04727554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 994
Description: Administered as an intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 994
Description: Administered as an intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 994
Description: Administered as an intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 994
Description: Administered as an intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 404
Description: Administered as an intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 404
Description: Administered as an intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 404
Description: Administered as an intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 404
Description: Administered as an intravenous (IV) infusion.
Study: NCT06470568

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Resistance exercise training
Description: The training sessions will begin with a 5-minute warm-up on a cycle ergometer and global movements involving the upper limbs. Following this, participants will perform one additional warm-up set, followed by four regular sets on both the leg press and leg extension machines. Upper body exercises will then be conducted on the chest press, pull-up, and horizontal rowing machines, with each exercise comprising 2 sets.~To conclude each session, there will be a 5-minute cooldown period involving global muscle stretching exercises. During the initial 6-week period, the workload will progressively increase from 60% to 80% of 1RM (10 repetitions per set). Subsequently, the 1RM will be reassessed to adjust workloads (maintaining 60%-80%) for the subsequent 6-week period. Compliance for per-protocol analysis will require participants to complete at least 80% of the training sessions (i.e., a minimum of 29 out of 36 sessions).
Study: NCT05400811

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo subcutaneous
Description: The same solution, presentation, method of administration, frequency, and duration as the active treatment, but without active ingredients.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo subcutaneous
Description: The same solution, presentation, method of administration, frequency, and duration as the active treatment, but without active ingredients.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo sublingual
Description: The same solution, presentation, method of administration, frequency, and duration as the active treatment, but without active ingredients.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo sublingual
Description: The same solution, presentation, method of administration, frequency, and duration as the active treatment, but without active ingredients.